natgillin/translations-raw huggingface dataset:
‘Slowing down/reduce the destruction process of cartilage of the musculoskeletal system and consequently reduce the risk of osteoarthritis’.
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 29. oktobra 2009, ugotovila, da vzročno-posledična povezava med uživanjem glukozamin hidroklorida in navedeno trditvijo ni bila utemeljena.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 29 October 2009 that a cause and effect relationship had not been established between the consumption of glucosamine hydrochloride and the claimed effect.
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Evropsko združenje proizvajalcev naravnih živil iz soje (European Natural Soyfood Manufacturers Association, ENSA), Evropska zveza za rastlinske beljakovine (European Vegetable Protein Federation, EUVEPRO) in Združenje za sojine beljakovine (Soya Protein Association, SPA) so v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložili vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki izolirane sojine beljakovine na znižanje koncentracije LDL-holesterola v krvi (vprašanje št.
Following an application from the European Natural Soyfood Manufacturers Association (ENSA), the European Vegetable Protein Federation (EUVEPRO) and the Soya Protein Association (SPA), submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of isolated soy protein on reduction of blood LDL-cholesterol concentrations (Question No EFSA-Q-2011-00784) [6].
EFSA-Q-2011-00784) [6].
‘Protein-rich soybean component has been shown to lower/reduce blood cholesterol; blood cholesterol lowering may reduce the risk of (coronary) heart disease’.
„Beljakovinsko bogata sestavina soje dokazano znižuje holesterol v krvi.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 2 February 2012 that a cause and effect relationship had not been established between the consumption of isolated soy protein, as defined by the applicant, and the claimed effect.
Znižanje holesterola v krvi lahko zmanjša tveganje za (koronarno) bolezen srca.“
Following an application from Health Concern B.V., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a combination of plant sterols and Cholesternorm®mix and reduction of blood LDL-cholesterol concentrations (Question No EFSA-Q-2009-00237, EFSA-Q-2011-01114) [7].
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 2. februarja 2012, ugotovila, da vzročno-posledična povezava med uživanjem izolirane sojine beljakovine, kot jo je opredelil vložnik, in navedeno trditvijo ni bila utemeljena.
‘Actively lowers cholesterol’.
Družba Health Concern B.V. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije rastlinskih sterolov in mešanice Cholesternorm® na znižanje koncentracije LDL-holesterola v krvi (vprašanji št.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 17 July 2012 that a cause and effect relationship had not been established between the consumption of a combination of plant sterols and Cholesternorm®mix and the claimed effect at the proposed conditions of use.
EFSA-Q-2009-00237, EFSA-Q-2011-01114) [7].
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
„Aktivno znižuje holesterol.“
Following an application from Minami Nutrition Health BVBA, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of eicosapentaenoic acid (EPA) on a reduction of the Arachidonic Acid (AA)/EPA ratio in blood in children with attention deficit hyperactivity disorder (ADHD) (Question No EFSA-Q-2012-00573) [8].
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 17. julija 2012, ugotovila, da vzročno-posledična povezava med uživanjem kombinacije rastlinskih sterolov in mešanice Cholesternorm® pod predlaganimi pogoji uporabe ter navedeno trditvijo ni bila utemeljena.
The claim proposed by the applicant was worded as follows:
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
‘EPA has been shown to reduce the AA/EPA ratio in blood.
Družba Minami Nutrition Health BVBA je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki eikozapentaenojske kisline (EPA) na znižanje razmerja arahidonska kislina (AA)/EPA v krvi otrok s primanjkljajem pozornosti in motnjo hiperaktivnosti (ADHD) (vprašanje št.
A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms.
EFSA-Q-2012-00573) [8].
These children are also characterised by less hyperactivity and/or coexisting oppositional behaviour’.
Vložnik je predlagal naslednjo trditev:
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 8 April 2013 that the target population for the claim is a diseased population (i.e. children with ADHD) and that the claimed effect relates to the treatment of a disease.
„EPA dokazano znižuje razmerje AA/EPA v krvi.
Regulation (EC) No 1924/2006 complements the general principles of Directive 2000/13/EC of the European Parliament and of the Council of 20 March 2000 on the approximation of the laws of the Member States relating to the labelling, presentation and advertising of foodstuffs [9].
Visoko razmerje AA/EPA je dejavnik tveganja za nastanek motenj pozornosti pri otrocih s simptomi, podobnimi ADHD.
Article 2(1)(b) of Directive 2000/13/EC provides that the labelling shall not attribute to any foodstuff the property of preventing, treating or curing a human disease, or refer to such properties.
Za te otroke je prav tako značilna manjša hiperaktivnost in/ali sočasno nasprotujoče obnašanje.“
Accordingly, as the attribution of medicinal properties to foods is prohibited, the claim related to the effects of eicosapentaenoic acid (EPA) on a reduction of the AA/EPA ratio in blood in children with ADHD should not be authorised.
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 8. aprila 2013, ugotovila, da so ciljna populacija za trditev bolniki (tj. otroci z ADHD) in da se navedena trditev nanaša na zdravljenje bolezni.
Following an application from McNeil Nutritionals and Raisio Nutrition Ltd, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the consumption of 2 g/day of plant stanols (as plant stanol esters) as part of a diet low in saturated fat and a two-fold greater reduction in blood LDL-cholesterol concentrations compared to the consumption of a diet low in saturated fat alone (Question No EFSA-Q-2012-00915) [10].
Uredba (ES) št. 1924/2006 dopolnjuje splošne določbe Direktive 2000/13/ES Evropskega parlamenta in Sveta z dne 20. marca 2000 o približevanju zakonodaje držav članic o označevanju, predstavljanju in oglaševanju živil [9].
‘Consuming 2 g/day plant stanols (as plant stanol esters) as part of a diet low in saturated fat results in a 2-fold greater reduction in LDL-cholesterol than consuming a low saturated fat diet alone.
Člen 2(1)(b) Direktive 2000/13/ES določa, da označevanje živilom ne sme pripisovati lastnosti, kot so preprečevanje, zdravljenje ali ozdravljenje bolezni pri ljudeh ali opozarjati na take lastnosti.
High cholesterol is a risk factor in the development of coronary heart disease’.
Ker je pripisovanje zdravilnih lastnosti živilom prepovedano, se trditev v zvezi z učinki eikozapentaenojske kisline (EPA) na znižanje razmerja AA/EPA v krvi otrok z ADHD ne bi smela odobriti.
On the basis of the data presented, the Authority concluded in its opinion received by the Commission and the Member States on 8 April 2013 that the evidence provided by the applicant does not establish that the consumption of 2 g/day plant stanols (as plant stanol esters) as part of a diet low in saturated fat results in a two-fold greater reduction in LDL-cholesterol concentrations compared with consuming a diet low in saturated fat alone.
Družba McNeil Nutritionals and Raisio Nutrition Ltd. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi, da uživanje 2 g/dan rastlinskih stanolov (v obliki estrov rastlinskih stanolov) v okviru prehrane z nizko vsebnostjo nasičenih maščob zniža koncentracijo LDL-holesterola v krvi dvakrat več kot le prehrana z nizko vsebnostjo nasičenih maščob (vprašanje št.
The comments from the applicants and the members of the public received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
EFSA-Q-2012-00915) [10].
The addition of substances to or the use of substances in foodstuffs is governed by specific Union and national legislation, as is the classification of products as foodstuffs or medicinal products.
„Uživanje 2 g/dan rastlinskih stanolov (v obliki estrov rastlinskih stanolov) v okviru prehrane z nizko vsebnostjo nasičenih maščob, zniža LDL-holesterol dvakrat več kot le prehrana z nizko vsebnostjo nasičenih maščob.
Any decision on a health claim in accordance with Regulation (EC) No 1924/2006 such as inclusion in the list of permitted claims referred to in Article 14(1) thereof does not constitute an authorisation to the marketing of the substance on which the claim is made, a decision on whether the substance can be used in foodstuffs, or a classification of a certain product as a foodstuff.
Povišan holesterol je dejavnik tveganja za razvoj koronarne bolezni srca.“
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,
Agencija je na podlagi predloženih podatkov v mnenju, ki so ga Komisija in države članice prejele 8. aprila 2013, ugotovila, da iz dokazov, ki jih je predložil vložnik, ni mogoče sklepati, da uživanje 2 g/dan rastlinskih stanolov (v obliki estrov rastlinskih stanolov) v okviru prehrane z nizko vsebnostjo nasičenih maščob zniža koncentracijo LDL-holesterola v krvi dvakrat več kot le prehrana z nizko vsebnostjo nasičenih maščob.
The health claims listed in Annex I to this Regulation may be made on foods placed on the Union market in compliance with the conditions laid down in that Annex.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vložniki in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
The health claims referred to in paragraph 1 shall be included in the Union list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
Dodajanje snovi živilom oziroma njihovo uporabo v živilih ter razvrstitev proizvodov med živila ali zdravila urejata posebna zakonodaja Unije in nacionalna zakonodaja.
The health claims listed in Annex II to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
Vsaka odločitev o zdravstveni trditvi v skladu z Uredbo (ES) št. 1924/2006, kot je vključitev na seznam dovoljenih trditev iz člena 14(1) navedene uredbe, ne pomeni dovoljenja za trženje snovi, na katero se trditev nanaša, odločitve o tem, ali se snov lahko uporablja v živilih, ali uvrstitve določenega proizvoda med živila.
OJ L 404, 30.12.2006, p. 9.
Zdravstvene trditve iz Priloge I k tej uredbi se lahko navedejo na živilih, ki se dajejo na trg Evropske unije, v skladu s pogoji iz navedene priloge.
EFSA Journal (2009) 1180, 1-13.
Zdravstvene trditve iz odstavka 1 se uvrstijo na seznam dovoljenih trditev Unije v skladu s členom 14(1) Uredbe (ES) št. 1924/2006.
EFSA Journal (2010);8(5):1609.
Zdravstvene trditve iz Priloge II k tej uredbi se ne uvrstijo na seznam dovoljenih trditev Unije v skladu s členom 14(1) Uredbe (ES) št. 1924/2006.
EFSA Journal 2009;7(10):1358.
UL L 404, 30.12.2006, str. 9.
EFSA Journal 2012;10(2):2555.
EFSA Journal 2009; 1180, 1–13.
EFSA Journal 2012;10(7):2810.
EFSA Journal 2010; 8(5):1609.
EFSA Journal 2013;11(4):3161.
EFSA Journal 2011; 9(9):2382.
OJ L 109, 6.5.2000, p. 29.
EFSA Journal 2009; 7(10):1358.
EFSA Journal 2013;11(4):3160.
EFSA Journal 2012; 10(2):2555.
ANNEX I
EFSA Journal 2012; 10(7):2810.
Permitted health claims
EFSA Journal 2013; 11(4):3161.
Application — Relevant provisions of Regulation (EC) No 1924/2006
UL L 109, 6.5.2000, str. 29.
Nutrient, substance, food or food category
PRILOGA I
Claim
Dovoljene zdravstvene trditve
Conditions of use of the claim
Vloga – ustrezne določbe Uredbe (ES) št. 1924/2006
Conditions and/or restrictions of use of the food and/or additional statement or warning
Vložnik – naslov
EFSA opinion reference
Hranilo, snov, živilo ali kategorija živil
Article 14(1)(a) health claim referring to a reduction of a disease risk
Trditev
Abtei Pharma Vertriebs GmbH, Abtei 1, 37696, Marienműnster, Germany .
Pogoji uporabe trditve
Calcium
Pogoji in/ali omejitve uporabe živila in/ali dodatno pojasnilo ali opozorilo
Calcium helps to reduce the loss of bone mineral in post-menopausal women.
Referenčno mnenje Agencije za varnost hrane
Low bone mineral density is a risk factor for osteoporotic bone fractures
Zdravstvena trditev po členu 14(1)(a), ki se nanaša na zmanjšanje tveganja za nastanek bolezni
The claim may be used only for food which provides at least 400 mg of calcium per quantified portion.
kalcij
Calcium and vitamin D
Trditev se lahko uporablja le na živilih, ki zagotavljajo vsaj 400 mg kalcija v količinsko določenem obroku.
Calcium and vitamin D help to reduce the loss of bone mineral in post-menopausal women.
Potrošnike je treba obvestiti, da je trditev namenjena zlasti ženskam po 50. letu starosti in da se koristni učinek doseže z dnevnim vnosom vsaj 1200 mg kalcija iz vseh virov.
The claim may be used only for food supplements which provide at least 400 mg of calcium and 15 μg of vitamin D per daily portion.
Trditev se lahko uporabi le na živilih z dodanim kalcijem, ki so namenjena ženskam po 50. letu starosti.
Information shall be given to the consumer that the claim is specifically intended for women 50 years and older and the beneficial effect is obtained with a daily intake of at least 1200 mg of calcium and 20 μg of vitamin D from all sources.
kalcij in vitamin D
For food supplements with added calcium and vitamin D the claim may be used only for those targeting women 50 years and older
Kalcij in vitamin D prispevata k zmanjšanju izgube mineralne kostne gostote pri ženskah po menopavzi.
DSM Nutritional Products Europe AG, P.O. Box 2676, 4002 Basel, Switzerland .
Trditev se lahko uporablja le na prehranskih dopolnilih, ki zagotavljajo vsaj 400 mg kalcija in 15 μg vitamina D v dnevnem odmerku.
Vitamin D
Potrošnike je treba obvestiti, da je trditev namenjena zlasti ženskam po 50. letu starosti in da se koristni učinek doseže z dnevnim vnosom vsaj 1200 mg kalcija in 20 μg vitamina D iz vseh virov.
Vitamin D helps to reduce the risk of falling associated with postural instability and muscle weakness.
Trditev se lahko uporabi le na prehranskih dopolnilih z dodanim kalcijem in vitaminom D, ki so namenjena ženskam po 50. letu starosti.
Falling is a risk factor for bone fractures among men and women 60 years of age and older.
Vitamin D prispeva k zmanjšanju tveganja za padce, ki so posledica slabšega ravnotežja in mišične oslabelosti.
The claim may be used only for food supplements which provide at least 15 μg of vitamin D per daily portion.
Padci so dejavnik tveganja za zlome kosti pri moških in ženskah po 60. letu starosti.
For food supplements with added vitamin D the claim may be used only for those targeting men and women 60 years and older
Potrošnike je treba obvestiti, da se koristni učinek doseže z dnevnim vnosom 20 μg vitamina D iz vseh virov.
ANNEX II
Trditev se lahko uporabi le na prehranskih dopolnilih z dodanim vitaminom D, ki so namenjena moškim in ženskam po 60. letu starosti.
Rejected health claims
PRILOGA II
Glucosamine hydrocloride
Zavrnjene zdravstvene trditve
Slowing down/reduce the destruction process of cartilage of the musculoskeletal system and consequently reduce the risk of osteoarthritis.
glukozamin hidroklorid
Isolated soy protein
Upočasni/zmanjša postopek uničevanja hrustanca v mišično-skeletnem sistemu in posledično zmanjša tveganje za osteoartritis.
Protein-rich soybean component has been shown to lower/reduce blood cholesterol; blood cholesterol lowering may reduce the risk of (coronary) heart disease.
izolirana sojina beljakovina
Plant sterols in combination with Cholesternorm®mix
rastlinski steroli v kombinaciji z mešanico Cholesternorm®
Actively lowers cholesterol.
Aktivno znižuje holesterol.
A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms.
Visoko razmerje AA/EPA je dejavnik tveganja za nastanek motenj pozornosti pri otrocih s simptomi, podobnimi ADHD.
Plant stanols (as plant stanol esters)
rastlinski stanoli (v obliki estrov rastlinskih stanolov)
Consuming 2 g/day plant stanols (as plant stanol esters) as part of a diet low in saturated fat results in a 2-fold greater reduction in LDL-cholesterol than consuming a low saturated fat diet alone.
Uživanje 2 g/dan rastlinskih stanolov (v obliki estrov rastlinskih stanolov) v okviru prehrane z nizko vsebnostjo nasičenih maščob zniža LDL-holesterol dvakrat več kot le prehrana z nizko vsebnostjo nasičenih maščob.
Commission Regulation (EU) No 1229/2014
Uredba Komisije (EU) št. 1229/2014
Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods [1], and in particular Article 18(5) thereof,
ob upoštevanju Uredbe (ES) št. 1924/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o prehranskih in zdravstvenih trditvah na živilih [1] ter zlasti člena 18(5) Uredbe,
Following an application from Italsur S.r.l., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of Tuscan black cabbage, ‘tri-coloured’ Swiss chard, ‘bi-coloured’ spinach and ‘blu savoy’ cabbage and protection of blood lipids from oxidative damage (Question No EFSA-Q-2013-00574) [2].
Družba Italsur s.r.l. je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije toskanskega črnega zelja, tribarvne blitve, dvobarvne špinače in modrega savojskega zelja na zaščito krvnih lipidov pred oksidativnimi poškodbami (vprašanje št.
The claim proposed by the applicant was worded as follows:
EFSA-Q-2013-00574) [2].
‘contributes to the protection of blood lipids from oxidative damage’.
Vložnik je predlagal naslednjo trditev:
On 30 October 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of Tuscan black cabbage, ‘tri-coloured’ Swiss chard, ‘bi-coloured’ spinach and ‘blu savoy’ cabbage and the claimed effect.
„Prispeva k zaščiti krvnih lipidov pred oksidativnimi poškodbami.“
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Komisija in države članice so 30. oktobra 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kombinacije toskanskega črnega zelja, tribarvne blitve, dvobarvne špinače in modrega savojskega zelja ter navedeno trditvijo ni utemeljena.
Following an application from Italsur S.r.l., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of red spinach, green spinach, red chicory, green chicory, green leaf chard, red leaf chard, red Swiss chard, golden Swiss chard and white Swiss chard and protection of blood lipids from oxidative damage (Question No EFSA-Q-2013-00575) [3].
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
On 30 October 2013, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of red spinach, green spinach, red chicory, green chicory, green leaf chard, red leaf chard, red Swiss chard, golden Swiss chard and white Swiss chard and the claimed effect.
Družba Italsur s.r.l. je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije rdeče špinače, zelene špinače, rdečega radiča, zelenega radiča, zelene listnate blitve, rdeče listnate blitve, rdeče blitve, zlate blitve in bele blitve na zaščito krvnih lipidov pred oksidativnimi poškodbami (vprašanje št.
Following an application from Italsur S.r.l., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of Tuscan black cabbage, ‘tri-coloured’ Swiss chard, ‘bi-coloured’ spinach and ‘blu savoy’ cabbage and maintenance of normal blood LDL-cholesterol concentration (Question No EFSA-Q-2013-00576) [4].
EFSA-Q-2013-00575) [3].
‘maintains normal blood cholesterol concentration’.
Komisija in države članice so 30. oktobra 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kombinacije rdeče špinače, zelene špinače, rdečega radiča, zelenega radiča, zelene listnate blitve, rdeče listnate blitve, rdeče blitve, zlate blitve in bele blitve ter navedeno trditvijo ni utemeljena.
Following an application from Italsur S.r.l., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of red spinach, green spinach, red chicory, green chicory, green leaf chard, red leaf chard, red Swiss chard, golden Swiss chard and white Swiss chard and maintenance of normal blood LDL-cholesterol concentration (Question No EFSA-Q-2013-00579) [5].
Družba Italsur s.r.l. je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki kombinacije toskanskega črnega zelja, tribarvne blitve, dvobarvne špinače in modrega savojskega zelja na vzdrževanje normalne koncentracije LDL-holesterola v krvi (vprašanje št.
‘maintain normal blood cholesterol concentrations’.
EFSA-Q-2013-00576) [4].
Following an application from Omikron Italia S.r.l., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of diosmin, troxerutin and hesperidin and maintenance of normal venous-capillary permeability (Question No EFSA-Q-2013-00353) [6].
„Vzdržuje normalno koncentracijo holesterola v krvi.“